Elevated serum level of B‐cell activating factor ( BAFF ) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with anti‐BAFF agents

Pemphigus patients with initial negative levels of anti‐desmoglein: A subtype with different profile?

(2022) Kamran Balighi et al.   Dermatologic Therapy

Evaluating the risk‐to‐benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: A retrospective study with 494 patients

(2021) Hannaneh Faraji et al.   Dermatologic Therapy

Pharmacological advances in pemphigus

(2019) Asli Bilgic Temel et al.   CURRENT OPINION IN PHARMACOLOGY

The safety of belimumab for the treatment of systemic lupus erythematosus

(2019) Leanna M Wise et al.   Expert Opinion On Drug Safety

Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches

(2018) Robert Pollmann et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Rituximab in pemphigus

(2018) Vivien Hebert et al.   Immunotherapy

Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review

(2018) Soheil Tavakolpour et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?

(2018) Kamran Balighi et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?

(2017) Soheil Tavakolpour   INTERNATIONAL IMMUNOPHARMACOLOGY

Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab

(2017) Lauren N. Albers et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

(2017) Pascal Joly et al.   LANCET

Pemphigus

(2017) Michael Kasperkiewicz et al.   Nature Reviews Disease Primers

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

(2016) C. T. Ellebrecht et al.   SCIENCE

The BAFF/APRIL system in SLE pathogenesis

(2014) Fabien B. Vincent et al.   Nature Reviews Rheumatology

The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus

(2012) Anne Davidson   Current Rheumatology Reports

Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses

(2011) Ron J Feldman et al.   Expert Review of Clinical Immunology

Belimumab

(2011) Iñaki Sanz et al.   NATURE REVIEWS DRUG DISCOVERY

Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity

(2010) William Stohl et al.   ARTHRITIS AND RHEUMATISM

The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases

(2010) Nichola Cooper et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

ELISA Testing of Anti–Desmoglein 1 and 3 Antibodies in the Management of Pemphigus

(2009) Claire Abasq et al.   ARCHIVES OF DERMATOLOGY

BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion

(2009) Mitchell Thorn et al.   CELLULAR IMMUNOLOGY